Obesity, a health burden of a global nature

Acta Pharmacologica Sinica

Volumn 33, Issue 2, 2012, Pages 145-147

  Zhang, Zhi Yun ^a   Wang, Ming Wei ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEBUTAMONE PLUS ZONISAMIDE; AMFEPRAMONE; APPETITE STIMULANT; BENZPHETAMINE; CETILISTAT; GSK 1521498; GSK 598809; INSULIN; INTERLEUKIN 1; LIRAGLUTIDE; LORCASERIN; LY 377604; MONOCYTE CHEMOTACTIC PROTEIN 1; PF 04620110; PF 04971729; PHENDIMETRAZINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VELNEPERIT; ZGN 433;

BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; CHINA; DEVELOPED COUNTRY; ENVIRONMENTAL FACTOR; HEALTH CARE COST; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIMARY HEALTH CARE; REVIEW;

ANTI-OBESITY AGENTS; HUMANS; OBESITY; RISK FACTORS;

EID: 84863174383     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.185     Document Type: Review

References (19)

1. Wang YF, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity 2008; 16: 2323-30.
2. Finkelstein EA, Ruhm CJ, Kosa KM. Economic causes and consequences of obesity. Annu Rev Publ Health 2005; 26: 239-57. (Pubitemid 40547383)
3. Wu YF. Overweight and obesity in China. Br Med J 2006; 333: 362-3.
4. Cheng TO, Ji CY. Prevalence and geographic distribution of childhood obesity in China in 2005. Int J Cardiol 2008; 131: 1-8.
5. Dixon JB. The effect of obesity on health outcomes. Mol Cell Endo-crinol 2009; 316: 104-8.
6. Friedman JM. Obesity causes and control of excess body fat. Nature 2009; 459: 340-2.
7. Zhang ZY, Zeng JJ, Kjaergaard M, Guan N, Raun K, Nilsson C, et al. Effects of a maternal diet supplemented with chocolate and fructose beverage during gestation and lactation on rat dams and their offspring. Clin Exp Pharmacol Physiol 2011; 38: 613-22.
8. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-45.
9. Tseng YH, Cypess AM, Kahn CR. Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov 2010; 9: 465-81.
10. Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther 2011; 90: 40-51.
11. Caveney E, Caveney BJ, Somaratne R, Turner JR, Gourgiotis L. Pharmaceutical interventions for obesity: a public health perspective. Diabetes Obes Metab 2011; 13: 490-7.
12. Sayburn A. Withdrawal of sibutramine leaves European doctors with just one obesity drug. Br Med J 2010; 340: c477.
13. Bray GA. Drug insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 89-95. (Pubitemid 40790155)
14. Bifulco M, Pisanti S. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion. Nat Rev Drug Discov 2009; 8: 594.
15. Jones D. Suspense builds on anti-obesity rollercoaster ride. Nat Rev Drug Discov 2011; 10: 5-6.
16. Small CJ, Bloom SR. Gut hormones as peripheral anti obesity targets. Curr Drug Targets CNS Neurol Disord 2004; 3: 379-88. (Pubitemid 39545296)
17. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100. (Pubitemid 40616618)
18. Astrup A, Rossner S, Van Goal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-16.
19. He M, Su HR, Gao WW, Johansson SM, Liu Q, Wu XY, et al. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice. PLoS ONE 2010; 5: e14205.